Welcome to our dedicated page for Petros Pharmaceuticals SEC filings (Ticker: PTPI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings for Petros Pharmaceuticals, Inc. (PTPI) provide detailed insight into the company’s technology-focused strategy, capital structure, and listing status. Through its periodic and current reports, investors can review how Petros describes its shift toward a SaaS and Software-as-a-Medical-Device (SaMD) platform designed to support prescription-to-over-the-counter (Rx-to-OTC) switches under U.S. Food and Drug Administration (FDA) guidance, including the "Nonprescription Drug Product with an Additional Condition for Nonprescription Use" (ACNU) framework.
On this page, users can access Forms 10-K and 10-Q for information about Petros’ financial condition, discontinued operations, and deconsolidation of former subsidiaries such as Metuchen Pharmaceuticals LLC, Timm Medical Technologies, Inc., and Pos-T-Vac, LLC. These reports explain how the company classified those operations as discontinued and moved to deconsolidate their assets, liabilities, and equity from its consolidated balance sheet, as well as the impact of assignments for the benefit of creditors and license terminations.
Form 8-K current reports are particularly important for tracking material events. Petros has used 8-K filings to disclose notice of delisting from the Nasdaq Stock Market, the suspension of trading on Nasdaq and subsequent trading on OTC markets under the symbol PTPI, and Nasdaq’s intention to file Form 25 to remove the company’s common stock from listing and registration under Section 12(b) of the Exchange Act. Other 8-Ks describe corporate actions such as reverse stock splits, public offerings of common stock and warrants, and equity compensation grants of restricted stock units to directors and officers.
The Form 25 (Form 25-NSE) filed by Nasdaq is a key document confirming the removal of Petros’ common stock from listing and registration on the Nasdaq Stock Market LLC. While this filing affects exchange listing status, the company’s filings note that Petros remains subject to reporting obligations under Sections 13 and 15(d) of the Exchange Act and that its shares continue to trade on an OTC market.
Stock Titan’s platform presents these SEC filings alongside AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand complex disclosures about listing status, discontinued operations, capital raises, and governance decisions. Users can review 10-K and 10-Q reports for broader context, 8-Ks for event-driven updates, and Form 4 insider transaction reports (when filed) to monitor equity awards and other changes in beneficial ownership related to Petros Pharmaceuticals.
Petros Pharmaceuticals, Inc. reported an equity grant to one of its senior executives. Officer Fady Boctor, who serves as President & Chief Commercial Officer, received 500,000 restricted stock units (RSUs) of Petros common stock on 01/02/2026 at a stated price of $0 per unit.
According to the terms, 50% of these RSUs vested on the grant date, and the remaining 50% will vest on the six‑month anniversary of the grant date if he is still providing services to the company. Each RSU gives the right to receive one share of common stock. After this grant, Boctor beneficially owned 519,986 shares of Petros common stock, with amounts adjusted for the company’s 1‑for‑25 reverse stock split that became effective at 4:05 p.m. New York time on April 30, 2025.
Petros Pharmaceuticals, Inc. director Joshua Silverman reported a new equity award in the company’s common stock. On 01/02/2026, he received 4,375,000 restricted stock units (RSUs)$0, reflecting a compensatory grant. Half of these RSUs vested on the grant date, and the remaining half will vest on the six‑month anniversary of the grant, provided he continues providing services to the company.
Each RSU represents the right to receive one share of common stock with a par value of $0.0001 per share. Following this transaction, Silverman beneficially owned 4,415,450 shares of Petros Pharmaceuticals common stock directly. The reported amounts have been adjusted to reflect the company’s 1‑for‑25 reverse stock split of its common stock that became effective at 4:05 p.m. New York time on April 30, 2025.
Petros Pharmaceuticals, Inc. reported that its Board of Directors approved new equity awards for key directors and an executive officer. Effective January 2, 2026, the company granted a total of 7,250,000 restricted stock units (RSUs), including 4,375,000 RSUs to Chairman Joshua Silverman, 1,875,000 RSUs to director Bruce Bernstein, 500,000 RSUs to President and Chief Commercial Officer Fady Boctor, and 500,000 RSUs to director Wayne Walker. Each RSU gives the holder the right to receive one share of Petros common stock. Half of each grant vested on the grant date, with the remaining half scheduled to vest six months later, as long as the recipient continues providing services to the company. These RSU awards were issued outside the company’s 2020 Omnibus Incentive Compensation Plan and are governed by Petros’s standard Restricted Stock Unit Agreement.
Petros Pharmaceuticals, Inc. reported an equity award to a director on a Form 4. On 01/02/2026, a director received 500,000 restricted stock units (RSUs)$0 per unit. According to the filing, 50% of the RSUs vested on the grant date and the remaining 50% will vest on the six-month anniversary of the grant date, as long as the director continues providing services to the company on that vesting date. Each RSU corresponds to one share of common stock. Following this grant, the director is reported to beneficially own 506,333 shares of Petros Pharmaceuticals common stock. The filing notes that these share amounts have been adjusted for the company’s 1-for-25 reverse stock split that became effective on April 30, 2025.
Petros Pharmaceuticals, Inc. reported that a director acquired additional equity through a stock-based compensation grant. On 01/02/2026, the reporting person received 1,875,000 Restricted Stock Units (RSUs) of Petros common stock at a price of $0 per unit, recorded as an acquisition. Following this grant, the director beneficially owns 1,887,334 shares of common stock in direct ownership.
The filing explains that 50% of the RSUs vested on the grant date and the remaining 50% will vest on the six-month anniversary of the grant, provided the director is still providing services to the company at that time. Each RSU converts into one share of common stock. The share amounts in the filing have been adjusted to reflect the company’s previously effected 1-for-25 reverse stock split of its common stock.
Petros Pharmaceuticals, Inc. (PTPI) has had its common stock removed from listing and registration on the Nasdaq Stock Market LLC. Nasdaq filed a Form 25 under Section 12(b) of the Securities Exchange Act of 1934, certifying that it complied with its rules and the requirements of 17 CFR 240.12d2-2(b) to strike this class of securities from listing and/or registration. The filing is signed on behalf of Nasdaq by a hearings advisor, confirming Nasdaq’s action to delist PTPI’s common stock from the exchange.
Petros Pharmaceuticals (PTPI) filed its Q3 2025 10‑Q. The company exited legacy products, recorded a $6.97 million gain from assigning subsidiaries and a Vivus settlement, and reported nine‑month net income of $2.25 million. From continuing operations, it posted a loss of $4.16 million; large preferred-related deemed dividends and warrant items drove a nine‑month loss per share of $1.95.
Liquidity remains tight: cash was $6,070,266 and working capital was $3.4 million as of September 30, 2025, with substantial doubt about continuing as a going concern. Stockholders’ equity improved to $3,368,087 from a deficit at year‑end 2024. A February 2025 financing raised $9.6 million gross (about $8.5 million net). The company effected a 1‑for‑25 reverse split on April 30, 2025, and its common stock was delisted from Nasdaq and now trades on the OTC Market.
Capital structure shifted materially: investors exercised Series B warrants via alternative cashless exercise for 39,208,828 shares during the period. Common shares outstanding were 42,284,502 at September 30, 2025, and 42,372,260 as of November 12, 2025.
Petros Pharmaceuticals (PTPI) reported a Nasdaq delisting process. Nasdaq notified the company on November 3, 2025 that it intends to announce the delisting of Petros’ common stock. Nasdaq will file a Form 25 to deregister the stock under Section 12(b), and the delisting becomes effective ten days after that filing.
The stock was suspended from The Nasdaq Capital Market on May 22, 2025 and has traded on the OTCID Basic Market under “PTPI” since July 1, 2025. Petros states trading on the OTCID will continue without disruption, and the company will remain subject to reporting obligations under Sections 13 and 15(d) of the Exchange Act.
FAQ
What is the current stock price of Petros Pharmaceuticals (PTPI)?
What is the market cap of Petros Pharmaceuticals (PTPI)?
